The purpose of this study is to see if the investigational vaccines NefTat and gp120w61d are safe and tolerable in humans and to see how the immune system responds to the vaccines. There have been advances in the treatment and prevention of HIV, but the spread of HIV/AIDS is getting worse. HIV/AIDS is the main infectious cause of death in the world. A vaccine to prevent HIV disease is the best way to try to deal with this situation. Several vaccine products have been tested, but only 2 are still in trial. There is a need for a new product.

Condition	Treatment or Intervention	Phase
HIV Infections HIV Seronegativity	Vaccine: Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A  Vaccine: NefTat  Drug: AS02A Adjuvant  Vaccine: gp120W61D	Phase I

Further Study Details: 

Expected Total Enrollment:  84

Despite recent advances in the treatment and prevention of HIV disease, the epidemic is worsening throughout most of the world. HIV/AIDS is the leading cause of death in sub-Saharan Africa and the leading infectious cause of death in the world. An effective and inexpensive vaccine to prevent HIV disease remains as the best option to try to deal with this expanding epidemic. A number of vaccine products have been tested; however, only 2 have progressed to a Phase III trial, underscoring the need for new vaccine strategies.

Prior to study entry, participants have their risk status for HIV infection determined by a series of questions. Further eligibility is determined by results of physical exam, laboratory tests, and further questions. Blood is drawn on each study visit. Participants are assigned randomly to 1 of 4 study groups: Group I: NefTat or placebo. Groups II, III, and IV: NefTat and gp120 or placebo. Each group receives a different concentration of gp120. All immunizations are admixed with AS02A adjuvant. Vaccinations are administered intramuscularly at 3 time points (entry, 1 month, and 3 months). Product safety and immunogenicity are performed at designated time points; participants have about 11 clinic visits.

Ages Eligible for Study:  18 Years   -   60 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria

Participants may be eligible for this study if they:

• Are between 18 and 60 years of age.
• Are in good general health and meet laboratory test requirements.
• Have a CD4 count of 400 or more cells/mm3.
• Agree to use at least 1 of the following methods of contraception for at least 21 days before enrollment until the last protocol visit: condoms (male or female) with or without a spermicide, diaphragm or cervical cap with spermicide, IUD, or hormonal-based therapy (applies to women who are able to have children).
• Have access to a participating site and are willing to have follow-up for the entire study (12 months).
• Answer questions about their understanding of the study.
• Do not have hepatitis B or C.
• Are HIV-uninfected.

Exclusion Criteria

Participants may not be eligible for this study if they:

• Are pregnant or breast-feeding.
• Have recently received a vaccine.
• Have used experimental agents within 30 days before enrollment.
• Have received HIV vaccines or placebo in a previous HIV vaccine study.
• Have received blood products 120 days before HIV screening.
• Have received immunoglobulin (antibodies) 60 days before HIV screening.
• Have serious reactions to vaccines.
• Have problems with their immune system.
• Have cancer.
• Have used drugs that affect the immune system within the past 6 months.
• Have diabetes.
• Have a thyroid disease.
• Have unstable asthma.
• Are taking anti-tuberculosis drugs.
• Have seizures.
• Have a bleeding disorder.
• Have had their spleen removed.
• Have angioedema (a certain type of body tissue swelling).
• Have active syphilis.
• Have high blood pressure (unless controlled by medication).
• Have mental or emotional problems that make them unsuitable for the study.
• Have any medical, mental, or social condition; job responsibilities; or other responsibility that, in the opinion of the doctor, would interfere with the study.
• Have reactions to components of the vaccines.
• Are at high risk for contracting HIV.

Alabama
      Univ of Alabama at Birmingham, Birmingham,  Alabama,  35294,  United States
California
      San Francisco Dept of Hlth / AIDS Office, San Francisco,  California,  94102,  United States
      Mt Zion Hospital, San Francisco,  California,  94102,  United States
District of Columbia
      Johns Hopkins Bloomberg School of Public Health, Washington,  District of Columbia,  20037,  United States
Maryland
      Johns Hopkins Bloomberg School of Public Health, Baltimore,  Maryland,  21205,  United States
      Univ of Maryland Institute of Human Virology, Baltimore,  Maryland,  212011192,  United States
      JHU-CIR/DC, Baltimore,  Maryland,  21205,  United States
Massachusetts
      Harvard University / Brigham and Women's Hospital, Boston,  Massachusetts,  02115,  United States
      Harvard University/Brown University, Boston,  Massachusetts,  02115,  United States
      Fenway Community Health, Boston,  Massachusetts,  02115,  United States
Missouri
      Saint Louis University School of Medicine, Saint Louis,  Missouri,  63110,  United States
New York
      Columbia Univ, New York,  New York,  10032,  United States
      Univ of Rochester Med Ctr, Rochester,  New York,  14642,  United States
      New York Blood Ctr, Bronx,  New York,  10456,  United States
      New York Blood Center, New York,  New York,  10021,  United States
Rhode Island
      Miriam Hosp, Providence,  Rhode Island,  02906,  United States
Tennessee
      Vanderbilt Univ Hosp, Nashville,  Tennessee,  37232,  United States
      Vanderbilt Univ / Med Ctr North, Nashville,  Tennessee,  37232,  United States
Virginia
      Univ of Marlyand / Infectious Diseases Physicians, Fairfax,  Virginia,  United States
Washington
      Fred Hutchinson Cancer Research Ctr, Seattle,  Washington,  98109,  United States

Study chairs or principal investigators

Tom Evans,  Study Chair

Study ID Numbers:  HVTN 041
Record last reviewed:  August 2004
Last Updated:  April 7, 2005
Record first received:  December 4, 2001
ClinicalTrials.gov Identifier:  NCT00027365
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08